PD-L1

Open Access
Enhancement of anti-PD-L1 antibody plus anlotinib efficacy due to downregulation of PD-L1 in the micro-conduit endothelium within the tumor: a randomized double-blind trial
Cuicui Zhang, Tianqing Chu, Qiming Wang, Ying Cheng, Yongxiang Zhang, Ruili Wang, Leilei Ma, Chaonan Qian, Baohui Han and Kai Li

Cancer Biology & Medicine October 2024, 21 (10) 951-962; DOI: https://doi.org/10.20892/j.issn.2095-3941.2023.0423
You have access
The efficacies and biomarker investigations of anti-programmed death-1 (anti-PD-1)-based therapies for metastatic bone and soft tissue sarcoma
Jia Lu, Ting Li, Zhichao Liao, Hui Yu, Yongtian Zhao, Haixiao Wu, Zhiwu Ren, Jun Zhao, Ruwei Xing, Sheng Teng, Yun Yang, Xiangchun Li, Kexin Chen, Jonathan Trent and Jilong Yang

Cancer Biology & Medicine June 2022, 19 (6) 910-930; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0270
You have access
Immunology and immunotherapy in breast cancer
Vladimir Semiglazov, Andrey Tseluiko, Asel Kudaybergenova, Anna Artemyeva, Petr Krivorotko and Roman Donskih

Cancer Biology & Medicine May 2022, 19 (5) 609-618; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0597
You have access
Super-enhancer receives signals from the extracellular matrix to induce PD-L1-mediated immune evasion via integrin/BRAF/TAK1/ERK/ETV4 signaling
Panpan Ma, Xinxin Jin, Zhiwei Fan, Zhou Wang, Suhui Yue, Changyue Wu, Shiyin Chen, Yuanyuan Wu, Miaomiao Chen, Donghua Gu, Siliang Zhang, Renfang Mao and Yihui Fan

Cancer Biology & Medicine May 2022, 19 (5) 669-684; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0137
You have access
Morphine-3-glucuronide upregulates PD-L1 expression via TLR4 and promotes the immune escape of non-small cell lung cancer
Kaiyuan Wang, Jian Wang, Ting Liu, Wenwen Yu, Nan Dong, Chen Zhang, Wenbin Xia, Feng Wei, Lili Yang and Xiubao Ren

Cancer Biology & Medicine February 2021, 18 (1) 155-171; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0442
You have access
PD-L1 expression and its effect on clinical outcomes of EGFR-mutant NSCLC patients treated with EGFR-TKIs
Yuchen Bai, Xiaoxia Chen, Likun Hou, Jun Qian, Tao Jiang, Caicun Zhou and Maciej Ciebiada

Cancer Biology & Medicine November 2018, 15 (4) 434-442; DOI: https://doi.org/10.20892/j.issn.2095-3941.2018.0223
You have access
Key questions about the checkpoint blockade-are microRNAs an answer?
Mihnea Dragomir, Baoqing Chen, Xiao Fu and George A. Calin

Cancer Biology & Medicine May 2018, 15 (2) 103-115; DOI: https://doi.org/10.20892/j.issn.2095-3941.2018.0006
You have access
PD-1/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy
Long Jia, Qi Zhang and Rongxin Zhang

Cancer Biology & Medicine May 2018, 15 (2) 116-123; DOI: https://doi.org/10.20892/j.issn.2095-3941.2017.0086
You have access
Programmed cell death ligand-1 (PD-L1) expression by immunohistochemistry: could it be predictive and/or prognostic in non-small cell lung cancer?
Mari Mino-Kenudson

Cancer Biology & Medicine June 2016, 13 (2) 157-170; DOI: https://doi.org/10.20892/j.issn.2095-3941.2016.0009
You have access
Immuno-oncology combinations: raising the tail of the survival curve
Samuel J. Harris, Jessica Brown, Juanita Lopez and Timothy A. Yap

Cancer Biology & Medicine June 2016, 13 (2) 171-193; DOI: https://doi.org/10.20892/j.issn.2095-3941.2016.0015

Main menu

User menu

Search

PD-L1

Pages

Navigate

More Information

For Authors

Journal Services